Page 59 - Genentech News Today

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

(BPT) - For hematologist-oncologist Dr. Amitkumar Mehta, his passion is to help develop approaches to treat lymphoma, including immunotherapies and targeted therapies that are effective and tolerable. As a clinical

A new treatment appears to reduce food allergies in children and teens, according to interim clinical trial results.

(RTTNews) - Regenerative health provider Pacira BioSciences, Inc. (PCRX) announced Thursday that its Board of Directors has appointed Frank Lee as...

Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced...

Adding atezolizumab to treatment with carboplatin improved survival outcomes in patients with metastatic TNBC in a phase 2 trial. Adding atezolizumab to treatment with carboplatin improved survival outcomes in patients with metastatic TNBC in a phase 2 trial.

These companies from various corners of the globe are well positioned for the future.

The FDA has accepted for Priority Review the BLA for omalizumab for the reduction of allergic reactions in patients with food allergies.

It isn't the first drugmaker to partner with the chipmaker, and it won't be the last.

Its positioning in biotech will likely take a long while to pay off.